Alnylam Pharmaceuticals Appoints Amy Schulman as New Chair of Board, Michael Bonney Remains on Board
January 6, 2023
Trending News 🌥️
Alnylam Pharmaceuticals ($NASDAQ:ALNY) is a biopharmaceutical company dedicated to discovering and developing innovative medicines based on RNA interference. It has a wide portfolio of drugs in clinical development for the treatment of rare and other diseases. On Thursday, Alnylam Pharmaceuticals announced that Amy Schulman will become the new chair of the board, replacing Michael Bonney, who will remain on the board as a non-independent director. Bonney had been serving as executive chair for over a year prior to this announcement. Schulman brings with her a wealth of experience in the pharmaceutical, biotechnology, and health care industries. She currently serves as an independent director on the boards of Vertex Pharmaceuticals, Inc., and Juno Therapeutics, Inc. Commenting on her new role, Schulman said, “I am honored to assume the role of Chair of Alnylam’s Board and look forward to working with Mike and the rest of the Board to help the Company realize its remaining potential.
Alnylam has made significant progress in advancing its pipeline and I am eager to help accelerate the Company’s momentum as it enters this exciting new chapter.” Michael Bonney, who will remain on the board as a non-independent director said, “I am delighted that Amy has agreed to join us as Chair of the Board. Alnylam Pharmaceuticals is well positioned to drive forward its mission of discovering and developing innovative medicines. With the appointment of Amy Schulman as chair of the board, the company is sure to benefit from her extensive knowledge and experience.
Price History
As a result of this news, the company’s stock opened at $232.1 and closed at $225.7, representing a decrease of 3.1% from its prior closing price of $232.9. Amy Schulman is an experienced executive with a long history of leadership in the pharmaceutical industry and beyond. She was most recently the Executive Vice President and Chief Strategy Officer of Pfizer and prior to that, she served as the CEO of the biotechnology company DARA BioSciences. At Alnylam Pharmaceuticals, Schulman will bring her decades of experience in drug development, business strategy and legal matters to the table. He also serves as a director on several other public companies, such as Amicus Therapeutics and Editas Medicine.
Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines based on RNA interference. The company’s mission is to translate science into breakthrough medicines for patients with serious diseases. With its new board leadership, Alnylam Pharmaceuticals is well-positioned to deliver on its mission and continue to move forward in its mission to develop novel treatments for patients around the world. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Alnylam Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 960.92 | -1.18k | -109.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Alnylam Pharmaceuticals. More…
| Operations | Investing | Financing |
| -559.44 | -104.14 | 654.61 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Alnylam Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 3.54k | 3.6k | -0.55 |
Key Ratios Snapshot
Some of the financial key ratios for Alnylam Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 78.4% | – | -105.9% |
| FCF Margin | ROE | ROA |
| -65.7% | -1173.2% | -18.0% |
VI Analysis
ALNYLAM PHARMACEUTICALS is a medium risk investment according to the VI Risk Rating. This rating takes into account the financial and business fundamentals of the company and provides a reliable assessment of its long-term potential. The VI Risk Rating system has identified 3 risk warnings in ALNYLAM PHARMACEUTICALS’ balance sheet, cashflow statement, and non-financial aspects. These warnings are invaluable for investors, as they provide insight into the company’s financial health and can help inform decisions about whether or not to invest in ALNYLAM PHARMACEUTICALS. The VI Risk Rating system is an effective way to assess the financial health of a company and determine its risk level. It takes into account a variety of factors, including a company’s liquidity, debt, profitability, cashflow, and other non-financial indicators. By using this system, investors can get a comprehensive picture of the company’s financial and business fundamentals and make informed decisions about whether or not to invest in ALNYLAM PHARMACEUTICALS. The VI Risk Rating system is available on the VI App, which is designed to make assessing companies’ financial health easier and more convenient. The app provides investors with the information they need to make informed decisions about their investments and can be used to quickly assess the risk level of any company. Overall, ALNYLAM PHARMACEUTICALS is a medium risk investment according to the VI Risk Rating system. The system has identified 3 risk warnings in its balance sheet, cashflow statement, and non-financial aspects, which provide valuable insight into the company’s financial health. Investors who are interested in learning more about ALNYLAM PHARMACEUTICALS should register on the VI App to get access to the risk rating system and other useful features. More…
VI Peers
The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Alnylam’s competitors include Regeneron Pharmaceuticals Inc, Intellia Therapeutics Inc, and Novartis AG.
– Regeneron Pharmaceuticals Inc ($NASDAQ:REGN)
As of 2022, Regeneron Pharmaceuticals Inc has a market cap of 79.02B and a Return on Equity of 19.7%. The company is a biotech company that focuses on the discovery, development, and commercialization of medicines for the treatment of serious medical conditions.
– Intellia Therapeutics Inc ($NASDAQ:NTLA)
Intellia Therapeutics is a gene-editing company that focuses on developing therapeutics to treat serious diseases. The company has a market cap of $3.96 billion as of 2022 and a return on equity of -26.91%. Intellia’s gene-editing technology is based on CRISPR-Cas9, which is a naturally occurring bacterial system that can be used to target and edit specific genes. The company’s pipelines include programs for sickle cell disease, beta thalassemia, Huntington’s disease, and transthyretin amyloidosis.
– Novartis AG ($LTS:0QM7)
Novartis AG is a global pharmaceutical company with a market cap of 169.13B as of 2022. It has a Return on Equity of 24.65%. The company focuses on the discovery, development, and commercialization of healthcare products. Novartis’s products include over-the-counter and prescription drugs, vaccines, and diagnostic tools. The company has operations in over 140 countries and its products are sold in 180 countries.
Summary
Alnylam Pharmaceuticals is a biopharmaceutical company specializing in RNA interference therapeutics. The company’s stock price has recently declined, following the announcement of the appointment of Amy Schulman as the new Chair of the Board, with Michael Bonney remaining on the Board. Investors should be aware that Alnylam is still a relatively young company with a small market cap and limited product offerings. It is also highly dependent on the successful development of its pipeline products, which could increase the stock’s volatility in the near term.
Additionally, investors should remain mindful of the potential risks associated with investing in a biopharmaceutical company and should seek professional advice before making an investment decision.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
